This class’s mechanism (efferent arteriole dilation resulting in intraglomerular pressure reduction and mitigation of angiotensin II-mediated fibrosis) and trial evidence cemented its role in slowing CKD progression [18,19]. This evidence concerns the gene AGT and chronic kidney disease.